NYSE:TEVA

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. More Details


Snowflake Analysis

Fair value with moderate growth potential.


Similar Companies

Share Price & News

How has Teva Pharmaceutical Industries's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: TEVA's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

4.3%

TEVA

2.1%

US Pharmaceuticals

0.08%

US Market


1 Year Return

31.9%

TEVA

11.1%

US Pharmaceuticals

12.8%

US Market

Return vs Industry: TEVA exceeded the US Pharmaceuticals industry which returned 11.1% over the past year.

Return vs Market: TEVA exceeded the US Market which returned 12.8% over the past year.


Shareholder returns

TEVAIndustryMarket
7 Day4.3%2.1%0.08%
30 Day-4.1%-1.3%-1.8%
90 Day-26.6%5.1%7.2%
1 Year31.9%31.9%14.0%11.1%15.3%12.8%
3 Year-44.5%-44.8%27.5%18.0%39.2%29.9%
5 Year-82.4%-83.3%48.7%31.6%88.3%67.1%

Price Volatility Vs. Market

How volatile is Teva Pharmaceutical Industries's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Teva Pharmaceutical Industries undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: TEVA ($9.48) is trading below our estimate of fair value ($29.8)

Significantly Below Fair Value: TEVA is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: TEVA is poor value based on its PE Ratio (2590.9x) compared to the US Pharmaceuticals industry average (25x).

PE vs Market: TEVA is poor value based on its PE Ratio (2590.9x) compared to the US market (18.2x).


Price to Earnings Growth Ratio

PEG Ratio: TEVA is poor value based on its PEG Ratio (52.3x)


Price to Book Ratio

PB vs Industry: TEVA is good value based on its PB Ratio (0.7x) compared to the US Pharmaceuticals industry average (3.2x).


Next Steps

Future Growth

How is Teva Pharmaceutical Industries forecast to perform in the next 1 to 3 years based on estimates from 20 analysts?

49.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TEVA's forecast earnings growth (49.5% per year) is above the savings rate (2.2%).

Earnings vs Market: TEVA's earnings (49.5% per year) are forecast to grow faster than the US market (23.1% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: TEVA's revenue (0.8% per year) is forecast to grow slower than the US market (9.8% per year).

High Growth Revenue: TEVA's revenue (0.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: TEVA's Return on Equity is forecast to be low in 3 years time (18.9%).


Next Steps

Past Performance

How has Teva Pharmaceutical Industries performed over the past 5 years?

-27.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: TEVA has a large one-off loss of $2.6B impacting its June 30 2020 financial results.

Growing Profit Margin: TEVA became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: TEVA has become profitable over the past 5 years, growing earnings by -27% per year.

Accelerating Growth: TEVA has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: TEVA has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.2%).


Return on Equity

High ROE: TEVA's Return on Equity (-1%) is considered low.


Next Steps

Financial Health

How is Teva Pharmaceutical Industries's financial position?


Financial Position Analysis

Short Term Liabilities: TEVA's short term assets ($12.8B) exceed its short term liabilities ($11.8B).

Long Term Liabilities: TEVA's short term assets ($12.8B) do not cover its long term liabilities ($28.4B).


Debt to Equity History and Analysis

Debt Level: TEVA's debt to equity ratio (176.4%) is considered high.

Reducing Debt: TEVA's debt to equity ratio has increased from 54.2% to 176.4% over the past 5 years.

Debt Coverage: TEVA's debt is not well covered by operating cash flow (5.5%).

Interest Coverage: TEVA's interest payments on its debt are well covered by EBIT (3.4x coverage).


Balance Sheet


Next Steps

Dividend

What is Teva Pharmaceutical Industries's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate TEVA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate TEVA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TEVA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TEVA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: TEVA is not paying a notable dividend for the US market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TEVA's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure


CEO

Kare Schultz (59 yo)

2.83yrs

Tenure

US$11,596,564

Compensation

Mr. Kare Schultz has been the Chief Executive Officer, President and Director of Teva Pharmaceutical Industries Limited since November 1, 2017. Mr. Schultz is a seasoned veteran in the healthcare industry ...


CEO Compensation Analysis

Compensation vs Market: Kare's total compensation ($USD11.60M) is about average for companies of similar size in the US market ($USD11.35M).

Compensation vs Earnings: Kare's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Kare Schultz
President2.83yrsUS$11.60m0.051%
$ 5.2m
Eliyahu Kalif
Executive VP & CFO0.75yrUS$655.76kno data
Hafrun Fridriksdottir
Executive Vice President of Global R&D3.58yrsUS$4.38m0.0042%
$ 432.1k
Brendan O'Grady
Executive Vice President of North America Commercial2.83yrsUS$3.46m0.0014%
$ 141.3k
Gianfranco Nazzi
Executive Vice President of International Markets Commercial2.83yrsUS$3.45m0.0018%
$ 188.0k
Eric Drapé
Executive Vice President of Global Operations0.92yrno data0.0020%
$ 203.6k
Deborah Griffin
Senior VP & Chief Accounting Officerno datano datano data
Kevin Mannix
Senior Vice President of Investor Relationsno datano datano data
David Stark
Executive VP & Chief Legal Officer3.83yrsno data0.00027%
$ 28.0k
Lori Queisser
Senior VP & Global Compliance Officer5.25yrsno datano data
Mark Sabag
Executive VP1.67yrsUS$5.25m0.0023%
$ 234.8k
Sven Dethlefs
Executive Vice President of Global Marketing & Portfolio2.83yrsno data0.0019%
$ 195.3k

2.8yrs

Average Tenure

51yo

Average Age

Experienced Management: TEVA's management team is considered experienced (2.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Kare Schultz
President2.83yrsUS$11.60m0.051%
$ 5.2m
Nechemia Peres
Independent Director3.17yrsUS$355.76k0.0023%
$ 242.0k
Sol Barer
Independent Chairman of the Board3.58yrsUS$540.00k0.025%
$ 2.6m
Amir Elstein
Independent Director11.67yrsUS$340.51k0.18%
$ 19.2m
Gerald Lieberman
Independent Director5yrsUS$355.00k0.0033%
$ 340.7k
Roberto Mignone
Independent Director3.17yrsUS$340.00k0.0023%
$ 242.0k
Jean-Michel Halfon
Independent Director6.25yrsUS$320.45k0.0028%
$ 289.8k
Rosemary Crane
Independent Director5yrsUS$330.00k0.0031%
$ 317.9k
Janet Vergis
Independent Director0.25yrno datano data
Perry Nisen
Independent Director3.17yrsUS$320.00k0.0023%
$ 242.0k
Ronit Satchi-Fainaro
Independent Director2.25yrsUS$310.42k0.0016%
$ 167.2k
Abbas Hussain
Independent Directorno datano datano data

3.2yrs

Average Tenure

60.5yo

Average Age

Experienced Board: TEVA's board of directors are considered experienced (3.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Teva Pharmaceutical Industries Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Teva Pharmaceutical Industries Limited
  • Ticker: TEVA
  • Exchange: NYSE
  • Founded: 1901
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$10.388b
  • Shares outstanding: 1.10b
  • Website: https://www.tevapharm.com

Number of Employees


Location

  • Teva Pharmaceutical Industries Limited
  • 5 Basel Street
  • Petah Tikva
  • 4951033
  • Israel

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TEVANYSE (New York Stock Exchange)YesADR EACH CNV INTO 1 ORDUSUSDFeb 1982
TEVDB (Deutsche Boerse AG)YesADR EACH CNV INTO 1 ORDDEEURFeb 1982
TEVA NBMV (Bolsa Mexicana de Valores)YesADR EACH CNV INTO 1 ORDMXMXNFeb 1982
TEVASWX (SIX Swiss Exchange)YesADR EACH CNV INTO 1 ORDCHCHFFeb 1982
0LERLSE (London Stock Exchange)YesADR EACH CNV INTO 1 ORDGBUSDFeb 1982
TEVAWBAG (Wiener Boerse AG)YesADR EACH CNV INTO 1 ORDATEURFeb 1982
TEVJ.FOTCPK (Pink Sheets LLC)Ordinary SharesUSUSDJun 1994
TEVATASE (The Tel-Aviv Stock Exchange)Ordinary SharesILILSJun 1994

Biography

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, E ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/21 06:12
End of Day Share Price2020/09/18 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.